コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 h altered signaling events downstream of the erythropoietin receptor.
2 ivated JAK2 to induce phosphorylation of the erythropoietin receptor.
3 0(5) units/ml on cells that also express the erythropoietin receptor.
4 replaced with the cytoplasmic domain of the erythropoietin receptor.
5 lls engineered to coexpress Mpl receptor and erythropoietin receptor.
6 mutations of the SHP-1 binding domain of the erythropoietin receptor.
7 ge-restricted genes, including Klf1/Eklf and Erythropoietin receptor.
8 ed blood cells-that is caused by a truncated erythropoietin receptor.
9 ch as glucose and anion transporters and the erythropoietin receptor.
10 toward early differentiation with increased erythropoietin receptor.
11 lical dimerization motif found in the murine erythropoietin receptor.
12 tions between transferrin receptor-2 and the erythropoietin receptor.
13 gh its ability to transduce signals from the erythropoietin receptor.
14 his is similar to the K(d) of SOCS-3 for the erythropoietin receptor.
15 d virus envelope glycoprotein, gp55, and the erythropoietin receptor.
16 ytokine receptors such as growth hormone and erythropoietin receptors.
19 high doses (50 mug/kg i.p.) of an exogenous erythropoietin receptor agonist in an inflammation-induc
20 ed whether a novel, synthetic, peptide-based erythropoietin-receptor agonist (Hematide, Affymax) can
23 containing the intracellular portion of the erythropoietin receptor allowed cells normally dependent
24 FFV envelope glycoprotein interacts with the erythropoietin receptor and a short form of the receptor
25 as been proposed for the activation of human erythropoietin receptor and human growth hormone recepto
26 and negatively regulates signalling from the erythropoietin receptor and is likely to regulate other
27 , the thrombopoietin receptor (MPL), and the erythropoietin receptor and mutations of other genes inv
28 tracellular and transmembrane domains of the erythropoietin receptor and of the intracellular domain
29 ecies barrier exists between mouse and human erythropoietin receptor and that the human erythropoieti
30 hromosome 19p13.2/3, near genes encoding the erythropoietin receptor and the cytokine receptor-associ
31 trast to the acquired MPDs, mutations of the erythropoietin receptor and thrombopoietin receptor have
32 ociate with the IL-3 receptor beta chain and erythropoietin receptor and to inhibit signaling mediate
33 teraction of the viral protein gp55 with the erythropoietin receptor, and other host factors, drives
34 n receptor subunits, sucrase-isomaltase, the erythropoietin receptor, and two of the subunits of the
37 of human erythroblasts with mouse antihuman erythropoietin receptor antibody but not mouse immunopur
39 425 and 367 in the cytoplasmic domain of the erythropoietin receptor are required for the phosphoryla
40 -CSFR fused to the cytoplasmic domain of the erythropoietin receptor, are able to support the product
43 -9R alpha-chain, IL-2 receptor ss-chain, and erythropoietin receptor, can be polyubiquitinated and de
45 2R beta with either gamma c or the truncated erythropoietin receptor chain led to an array of specifi
46 sion systems: 1) 32D cells expressing leptin/erythropoietin receptor chimeras, 2) COS-7 cells express
47 R) signaling complex by a severely truncated erythropoietin receptor cytoplasmic domain lacking tyros
49 extracellular ligand-binding domains of the erythropoietin receptor, determined at 1.9 A from two cr
51 al regulator of erythropoiesis, cell surface erythropoietin receptors dimerize and activate specific
52 n the extracellular dimerization site of the erythropoietin receptor, distant from the hormone bindin
57 ning progressively truncated isoforms of the erythropoietin receptor (EPO-R) and determined the rate
58 d tyrosine phosphorylation of both c-kit and erythropoietin receptor (EPO-R) and significantly greate
63 expression of erythroid genes including the erythropoietin receptor (EPO-R) that results in increase
64 e cytokine erythropoietin (EPO), its cognate erythropoietin receptor (EPO-R), and associated Janus ty
66 93T cells heterologously expressing TRPC and erythropoietin receptor (Epo-R), Epo stimulated an incre
68 Here we show that erythroid progenitors from erythropoietin receptor (Epo-R)-/- fetal livers, infecte
71 rosine residue (pY) peptide derived from the erythropoietin receptor (EpoR pY429) binds to the N-SH2
74 protein, SFFV gp55, forms a complex with the erythropoietin receptor (EpoR) and a short form of the r
76 failing signal transduction at the homomeric erythropoietin receptor (EpoR) and at the heteromeric in
77 displays 100-fold increased affinity for the erythropoietin receptor (EPOR) and correspondingly eleva
78 Here, to clarify the functional role of the erythropoietin receptor (EpoR) and its downstream transc
79 Ba/F3 and B6SUtA cells transfected with the erythropoietin receptor (EpoR) and selected with erythro
80 ceptors with the extracellular domain of the erythropoietin receptor (EpoR) and the cytoplasmic domai
81 whether or not tyrosine residues within the erythropoietin receptor (EPOR) are essential for biologi
83 a model involves mitogenic activation of the erythropoietin receptor (EpoR) by the virus env gene (F-
85 2/p30) that are hyperphosphorylated in a DA3/erythropoietin receptor (EpoR) cell line that expresses
87 lls, we employed a prolactin receptor (PrlR)/erythropoietin receptor (EpoR) chimera system, in which
89 ane targeted chimeric protein containing the erythropoietin receptor (EpoR) cytoplasmic domain fused
91 n) scaffold, that can systematically control erythropoietin receptor (EpoR) dimerization orientation
92 e cytokine known to regulate erythropoiesis, erythropoietin receptor (EpoR) expression and associated
93 unoblotting and immunostaining have reported erythropoietin receptor (EpoR) expression in nonhematopo
94 In this issue of Blood, Li et al show that erythropoietin receptor (Epor) expression marks the cent
96 om the anemic strain (gp55-A), activates the erythropoietin receptor (EpoR) for proliferation of hema
98 any cancer cells show some expression of the erythropoietin receptor (EPOR) gene, although the "funct
99 utation affecting codon 399 in exon 8 of the erythropoietin receptor (EPOR) gene, encoding an EpoR pe
100 f red cell production through agonism of the erythropoietin receptor (EpoR) has historically been acc
101 able to bind to one of the 2 subunits of the erythropoietin receptor (EpoR) homodimer and is thus a c
103 ated with mutations in the gene encoding the erythropoietin receptor (EpoR) in a small number of fami
104 O) is used to treat anemia by activating the erythropoietin receptor (EPOR) in erythroid progenitor c
106 L traptamers) that specifically activate the erythropoietin receptor (EPOR) in mouse cells to confer
119 Using myleoid cells expressing a series of erythropoietin receptor (EpoR) mutants, we have demonstr
120 (EPO) regulates erythropoiesis by binding to erythropoietin receptor (Epor) on erythroid progenitor c
122 generate cells expressing high levels of the erythropoietin receptor (EpoR) or a dominant negative Sm
125 tions of the cytoplasmic domain of the human erythropoietin receptor (EPOR) result in a dominantly in
127 design of de novo TM proteins targeting the erythropoietin receptor (EpoR) TM domain in a custom bin
128 und and unbound forms, the activation of the erythropoietin receptor (EPOR) was initially proposed to
130 oprotein, gp55, constitutively activates the erythropoietin receptor (EPOR), causing uncontrolled ery
131 Ab12.6, an agonistic human Ab targeting the erythropoietin receptor (EPOR), exhibits several potenti
133 a homodimeric Type I cytokine receptor, the erythropoietin receptor (EpoR), the thrombopoietin recep
134 sly characterized a truncation mutant of the erythropoietin receptor (EpoR), which is associated with
135 erythroid-specific gene expression including erythropoietin receptor (EpoR), which suggests a novel m
136 Spry1 was discovered to be regulated via the erythropoietin receptor (EPOR), with marked EPO-induced
137 served in the content of beta-globin mRNA in erythropoietin receptor (EpoR)-transfected Ba/F3 cells b
141 n (Epo) can generate commitment cues via the erythropoietin receptor (EpoR); specifically, EpoR signa
142 ates growth hormone receptor (GHR-pY595) and erythropoietin receptor (EpoR-pY426) at 1.98 angstrom an
143 agents (ESAs) have been reported to activate erythropoietin receptors (EpoR) on cell types, including
144 n apparent Mr of 55,000 (gp55) that binds to erythropoietin receptors (EpoR) to stimulate erythroblas
145 ein with apparent Mr of 55,000 that binds to erythropoietin receptors (EpoR) to stimulate erythroblas
146 n specifically binds to and activates murine erythropoietin receptors (EpoRs) coexpressed in the same
147 by binding and orientating two cell-surface erythropoietin receptors (EPORs) which trigger an intrac
155 poietin expression and a tenfold increase in erythropoietin receptor expression, increased cell survi
157 escribe four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromo
159 vates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating
161 ermal growth factor receptor (ErbB1) and the erythropoietin receptor have indicated that interactions
162 lls, retroviral vectors containing the human erythropoietin receptor (hEpoR) gene were used to transd
163 d property of all EMAs, to bind on the human erythropoietin receptor (hEPOR), is therefore exploited.
166 onstrated a novel role of erythropoietin and erythropoietin receptor in cardiac development in vivo.
167 ty, and when overexpressed together with the erythropoietin receptor in cells, it caused hyperactivat
168 t-derived growth factor beta receptor or the erythropoietin receptor in cultured mouse cells, resulti
173 basic science studies on erythropoietin and erythropoietin receptors in solid cancers, raise concern
175 totic pathways, potentially activated by the erythropoietin receptor, interact to produce the remarka
176 The spectrum of progenitors targeted by the erythropoietin receptor is broader during stress than du
179 SPCs) can recreate the truncated form of the erythropoietin receptor, leading to substantial increase
180 f Tyr(985) does not alter STAT3 signaling by erythropoietin receptor-LRb (ELR) chimeras in transfecte
181 te is regulated at least in part through the erythropoietin receptor-mediated survival of splenic ear
182 in of SHP-1 with the tyrosine phosphorylated erythropoietin receptor modestly potentiated but was not
184 and beta common (beta c), whereas the normal erythropoietin receptor (nEpoR) comprises only one known
185 oetal liver, endocardium and myocardium, the erythropoietin receptor null mouse shows extensive apopt
187 osis in fetal liver, heart, and brain in the erythropoietin receptor null phenotype was markedly redu
188 iously demonstrated expression of endogenous erythropoietin receptor on murine myoblasts, and erythro
189 Erythropoietin induces dimerization of the erythropoietin receptor on the surface of erythroid prog
191 cal and suggests that studying modulation of erythropoietin receptor pathway may lead to strategies i
192 een focus forming virus, which activates the erythropoietin receptor; polyoma virus middle T antigen,
197 of C2C12 myoblasts overexpressing truncated erythropoietin receptor showed more transplanted cell in
198 system restores active hematopoiesis via the erythropoietin receptor/signal transducer and activator
201 kemia cell lines and enhances ligand-induced erythropoietin receptor signaling in erythroid progenito
202 ment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore
206 port the design and validation of two mutant erythropoietin receptors that probe the role of individu
207 se coding for alpha-globin, beta-globin, the erythropoietin receptor, the erythroid krupple-like fact
208 e kinases activated during engagement of the erythropoietin receptor, the Janus family kinase Jak-2 a
209 everal type I cytokine receptors, namely the erythropoietin receptor, the thrombopoietin receptor (Tp
210 trates of these kinases are tyrosines in the erythropoietin receptors themselves and the signal trans
211 iation (erythropoiesis), and truncated human erythropoietin receptors (thEpoR) have been reported in
212 cades are activated during engagement of the erythropoietin receptor to mediate the biological effect
213 ered to be refractory (the IL-6, leptin, and erythropoietin receptors), to suppressor of cytokine sig
214 revious study, it was found that a truncated erythropoietin receptor transgene (tEpoR tg) enables mul
215 n erythropoietin receptor and that the human erythropoietin receptor transgene is able to provide spe
217 c defect associated with embryos lacking the erythropoietin receptor was corrected and the increased
220 dentification of compounds that can dimerize erythropoietin receptor, we have developed a novel, high
221 corresponding to the extracellular domain of erythropoietin receptor were expressed in Escherichia co
222 teracting residues in the growth hormone and erythropoietin receptors, whereas Cys-161, Cys-210, and
224 of 100 mutants within the WSXWS motif of the erythropoietin receptor, which represents all single ami
225 ng the expression of the cDNA of a truncated erythropoietin receptor with a previously reported genom